These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 30467074)

  • 1. Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis.
    Sermet-Gaudelus I; Clancy JP; Nichols DP; Nick JA; De Boeck K; Solomon GM; Mall MA; Bolognese J; Bouisset F; den Hollander W; Paquette-Lamontagne N; Tomkinson N; Henig N; Elborn JS; Rowe SM
    J Cyst Fibros; 2019 Jul; 18(4):536-542. PubMed ID: 30467074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis.
    Beumer W; Swildens J; Leal T; Noel S; Anthonijsz H; van der Horst G; Kuiperij-Boersma H; Potman M; van Putten C; Biasutto P; Platenburg G; de Jonge H; Henig N; Ritsema T
    PLoS One; 2019; 14(6):e0219182. PubMed ID: 31251792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis.
    Drevinek P; Pressler T; Cipolli M; De Boeck K; Schwarz C; Bouisset F; Boff M; Henig N; Paquette-Lamontagne N; Montgomery S; Perquin J; Tomkinson N; den Hollander W; Elborn JS
    J Cyst Fibros; 2020 Jan; 19(1):99-107. PubMed ID: 31182369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cystic Fibrosis-Like Airway Surface Layer Is not a Significant Barrier for Delivery of Eluforsen to Airway Epithelial Cells.
    Brinks V; Lipinska K; de Jager M; Beumer W; Button B; Livraghi-Butrico A; Henig N; Matthee B
    J Aerosol Med Pulm Drug Deliv; 2019 Oct; 32(5):303-316. PubMed ID: 31120356
    [No Abstract]   [Full Text] [Related]  

  • 5. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
    Donaldson SH; Pilewski JM; Griese M; Cooke J; Viswanathan L; Tullis E; Davies JC; Lekstrom-Himes JA; Wang LT;
    Am J Respir Crit Care Med; 2018 Jan; 197(2):214-224. PubMed ID: 28930490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.
    Clancy JP; Rowe SM; Accurso FJ; Aitken ML; Amin RS; Ashlock MA; Ballmann M; Boyle MP; Bronsveld I; Campbell PW; De Boeck K; Donaldson SH; Dorkin HL; Dunitz JM; Durie PR; Jain M; Leonard A; McCoy KS; Moss RB; Pilewski JM; Rosenbluth DB; Rubenstein RC; Schechter MS; Botfield M; Ordoñez CL; Spencer-Green GT; Vernillet L; Wisseh S; Yen K; Konstan MW
    Thorax; 2012 Jan; 67(1):12-8. PubMed ID: 21825083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
    Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
    BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
    Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
    Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.
    Flume PA; Liou TG; Borowitz DS; Li H; Yen K; Ordoñez CL; Geller DE;
    Chest; 2012 Sep; 142(3):718-724. PubMed ID: 22383668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
    Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
    Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation.
    De Stefano D; Villella VR; Esposito S; Tosco A; Sepe A; De Gregorio F; Salvadori L; Grassia R; Leone CA; De Rosa G; Maiuri MC; Pettoello-Mantovani M; Guido S; Bossi A; Zolin A; Venerando A; Pinna LA; Mehta A; Bona G; Kroemer G; Maiuri L; Raia V
    Autophagy; 2014; 10(11):2053-74. PubMed ID: 25350163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.
    Hoppe JE; Chilvers M; Ratjen F; McNamara JJ; Owen CA; Tian S; Zahigian R; Cornell AG; McColley SA
    Lancet Respir Med; 2021 Sep; 9(9):977-988. PubMed ID: 33965000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).
    Kazani S; Rowlands DJ; Bottoli I; Milojevic J; Alcantara J; Jones I; Kulmatycki K; Machineni S; Mostovy L; Nicholls I; Nick JA; Rowe SM; Simmonds NJ; Vegesna R; Verheijen J; Danahay H; Gosling M; Ayalavajjala PS; Salman M; Strieter R
    J Cyst Fibros; 2021 Mar; 20(2):250-256. PubMed ID: 33293212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
    Boyle MP; Bell SC; Konstan MW; McColley SA; Rowe SM; Rietschel E; Huang X; Waltz D; Patel NR; Rodman D;
    Lancet Respir Med; 2014 Jul; 2(7):527-38. PubMed ID: 24973281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.
    Rowe SM; Liu B; Hill A; Hathorne H; Cohen M; Beamer JR; Accurso FJ; Dong Q; Ordoñez CL; Stone AJ; Olson ER; Clancy JP;
    PLoS One; 2013; 8(7):e66955. PubMed ID: 23922647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CF-CIRC study: a French collaborative study to assess the accuracy of cystic fibrosis diagnosis in neonatal screening.
    Sermet-Gaudelus I; Roussel D; Bui S; Deneuville E; Huet F; Reix P; Bellon G; Lenoir G; Edelman A
    BMC Pediatr; 2006 Oct; 6():25. PubMed ID: 17018149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.
    Rubenstein RC; Egan ME; Zeitlin PL
    J Clin Invest; 1997 Nov; 100(10):2457-65. PubMed ID: 9366560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.